Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 4-week study of Allegra dry syrup in pediatric perennial rhinitis
2017-000239-15Phase 3
- Sponsor
- Sanofi
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fexofenadine in perennial rhinitis, sponsored by Sanofi. Primary endpoints: Number of patients with adverse events (4-week safety) and Number of patients with adverse events (long-term safety up to 12 weeks).
02
Drugs
fexofenadine
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on 2017-000239-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000239-15.